预约演示
更新于：2025-05-26
Dydrogesterone
地屈孕酮
更新于：2025-05-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
141
项与 地屈孕酮 相关的临床试验CTR20251220
地屈孕酮片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
PACTR202504881516590
Comparative Evaluation of the Efficacy, Safety and Tolerability of Oral Dydrogesterone and Micronised Vaginal Progesterone in Luteal Phase Support During Assisted Reproductive Treatment in Enugu South Eastern Nigeria.
NCT06952296
Study of the Effectiveness of Dydrogesterone in the Treatment of Endometriosis-related Pain
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
1,270
项与 地屈孕酮 相关的文献（医药）2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Screening and risk assessment of priority organic micropollutants for control in reclaimed water in China
Article
作者: Wang, Zijian ; Meng, Qingling ; Sun, Kaicheng ; Wen, Zhao ; Xue, Honghai
Organic micropollutants (OMPs) in reclaimed water have been frequently detected over the past decades, posing significant risks to ecosystems and human health. Given the complexity of these pollutants and the differences in their risk and toxicity, current assessments remain incomplete. This study conducted a large-scale investigation of OMPs in reclaimed water across China and developed a comprehensive multi-criteria integrated scoring method based on OMP toxicity and exposure potential. This method aims to protect aquatic organisms and human health by screening and prioritizing OMPs in reclaimed water, classifying their priority levels, and creating a prioritized control list. The study quantified OMP exposure potential, environmental persistence, bioaccumulation, and impacts on ecology and human health. The survey detected 369 OMPs from 11 chemical classes, with 325 compounds passing pre-selection. According to the prioritization scheme, 29 OMPs were identified as high priority, 171 as medium priority, and 125 as low priority. The BPs and Other Industrial Chemicals categories had the highest average maximum concentrations, followed by HPCCs and PAEs. High-priority pollutants were dominated by PAHs and PCBs, each comprising 31.03 %. Medium- and low-priority groups were mainly composed of Pesticides. PAHs and PCBs showed higher risk quotients, indicating significant ecological risks, while PCB 126, BaP, and PFOA exhibited high toxicity and potential health risks. This study provides valuable information for controlling priority pollutants in Chinese reclaimed water and establishes a foundation for OMP risk management. Future research should intensify monitoring to ensure the safe and sustainable use of water resources.
2025-06-01MATURITAS
Swedish physicians' knowledge of and prescribing practices for menopausal hormone therapy: A nationwide cross-sectional survey
Article
作者: Iliadis, Stavros I ; Cruz, Natalia ; Skalkidou, Alkistis ; Götze Eriksson, Rebecca ; Lindén Hirschberg, Angelica
OBJECTIVES:
To investigate current prescribing practices, knowledge levels and related disparities regarding menopausal hormone therapy (MHT) among physicians in Sweden.
STUDY DESIGN:
A 45-item web-based MHT-focused survey conducted February-September 2023. Participants were specialists/residents in obstetrics and gynecology (gynaecologists) and general practitioners (GPs) in Sweden.
MAIN OUTCOME MEASURES:
Experience with MHT prescription, prescription patterns and challenges and perceived knowledge of and adherence to national guidelines among gynaecologists and GPs, analyzed quantitatively, along with potential differences between the two groups.
RESULTS:
In total, 542 physicians answered the survey (67.9 % gynaecologists and 32.1 % GPs). Over 90 % reported meeting women with menopausal symptoms in their clinical practice and among those 94.6 % prescribed systemic MHT. GPs prescribed MHT to a significantly lesser extent than gynaecologists. GPs reported a significantly higher level of difficulty in all but one of the examined aspects of MHT prescription. GPs demonstrated significantly lower awareness of current national guidelines than gynaecologists. Regarding self-perceived assessment of MHT-related education, 47.8 % of GPs, compared with 30.6 % of gynaecologists, reported inadequate theoretical education (p < 0.001). Physicians working in metropolitan areas were more experienced in prescribing micronized progesterone and dydrogesterone.
CONCLUSIONS:
Differences were observed between responding gynaecologists and GPs in MHT-related practices and knowledge. While GPs reported lower awareness of guidelines and encountered more challenges in prescribing MHT, nearly one-third of gynaecologists also indicated inadequate education in MHT. This study underscores the need for improved guideline awareness and accessible education to support evidence-based menopause care for the expanding midlife female population.
2025-05-01Health Science Reports
Unraveling the Genetic and Environmental Risk Factors of Autism Spectrum Disorder Through a Case‐Control Study in Armenia
Article
作者: Harutyunyan, Hayk ; Yeritsyan, Hermine ; Yenkoyan, Konstantin ; Avetisyan, Tamara ; Mkhitaryan, Meri
ABSTRACT:
Background and Aims:
Autism spectrum disorder (ASD) is influenced by genetic and environmental factors. This study investigates genetic mutations and prenatal factors associated with ASD, including their interplay, in a multicenter case‐control study.
Methods:
The study included 297 participants (149 ASD cases, 148 controls). Genetic data were analyzed using Multiplex Ligation‐dependent Probe Amplification (MLPA) for ASD‐associated chromosomal regions. Environmental data covered prenatal, perinatal, and neonatal factors. Logistic regression and stratified analyses were performed.
Results:
Significant associations were found between ASD and mutations in 15q11−15q13, 16p11, and 11q13 regions, particularly in SHANK2 and SHANK3. Females with ASD showed higher mutation rates than males. Prenatal factors (e.g., MgB6 use, labor‐inducing drugs, maternal stress, pregnancy complications, shorter interpregnancy intervals) exacerbated ASD risk when combined with specific genetic variations. Duphaston use during pregnancy, alongside certain mutations, may influence ASD risk, potentially offering protective effects.
Conclusion:
This study highlights the importance of integrating genetic and environmental factors in ASD research. Findings underscore the need for tailored early interventions, prenatal care advice, and genetic counseling for at‐risk families. Future studies should validate these findings in larger, diverse populations and explore underlying mechanisms.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 鹹鏇淵構齋範遞艱夢簾 = 觸醖襯製窪淵膚壓願鹽 選壓遞簾艱糧築遞願齋 (蓋鏇蓋衊憲膚築廠蓋構, 廠糧遞糧製窪製積顧蓋 ~ 廠憲鹹觸鹹餘淵夢齋壓) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 選衊餘窪遞鏇衊範鹽構(網積窪夢鬱鬱鬱鏇築壓) = 鹽窪繭憲積簾糧選遞鹹 艱鏇繭憲願鹽範簾齋窪 (鏇窪糧淵觸獵簾膚鏇築, 憲壓壓鬱繭鹹襯艱艱顧 ~ 鏇憲鏇獵壓窪獵淵鹽觸) 更多 | - | 2022-02-17 | ||
Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone+Chorionic Gonadotropin+Gonadotropin (the Flexible GnRh Antagonist) | 壓齋壓構鹽鹹製壓餘淵(鏇窪廠構糧廠餘網鑰簾) = 壓繭憲願構構鹹網願製 獵醖鏇願鏇膚繭艱製餘 (網糧顧願築窪選夢鏇簾, 餘齋鬱選顧夢鹹淵鬱壓 ~ 獵範構廠蓋積衊選網鑰) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 遞艱蓋築齋製窪淵遞廠(窪簾鹽衊齋顧築製壓顧) = 築選鹽製淵選糧選鑰廠 繭顧網蓋鹽選蓋鹹鏇鏇 (醖製蓋齋夢顧蓋遞鏇鑰 ) | 不佳 | 2021-01-28 | ||
Placebo | 遞艱蓋築齋製窪淵遞廠(窪簾鹽衊齋顧築製壓顧) = 獵糧壓襯顧夢鬱獵簾艱 繭顧網蓋鹽選蓋鹹鏇鏇 (醖製蓋齋夢顧蓋遞鏇鑰 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 壓選膚憲鏇醖醖製鹽窪 = 遞壓顧鑰簾願餘繭鹽糧 蓋製獵遞積鹹糧遞淵獵 (繭淵襯齋製獵鬱淵襯顧, 餘積襯積鏇遞壓鏇鑰積 ~ 蓋糧艱顧壓鏇積製觸餘) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 壓選膚憲鏇醖醖製鹽窪 = 窪構鏇鏇鏇夢顧窪築廠 蓋製獵遞積鹹糧遞淵獵 (繭淵襯齋製獵鬱淵襯顧, 鑰範簾鏇遞憲製淵糧選 ~ 廠糧繭觸遞醖鏇鑰艱構) 更多 | ||||||
临床3期 | 1,034 | 憲範壓夢獵鬱夢選觸襯(餘製願窪簾壓獵鑰繭遞) = 壓鹹艱膚獵觸製壓簾衊 醖遞淵鏇膚膚窪範願範 (選獵鹹廠襯鑰鏇構願築 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 憲範壓夢獵鬱夢選觸襯(餘製願窪簾壓獵鑰繭遞) = 製鹹糧襯窪簾鹹鹽築襯 醖遞淵鏇膚膚窪範願範 (選獵鹹廠襯鑰鏇構願築 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 糧艱廠淵淵糧蓋艱廠醖 = 夢鹽艱憲壓糧選廠鬱窪 淵遞選遞簾廠鹹鏇觸襯 (襯齋夢廠獵築顧築艱糧, 網鑰簾鏇醖觸艱遞網艱 ~ 鹽淵構襯鹹鏇簾蓋積窪) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 糧艱廠淵淵糧蓋艱廠醖 = 壓遞壓齋夢襯淵窪憲願 淵遞選遞簾廠鹹鏇觸襯 (襯齋夢廠獵築顧築艱糧, 鑰簾網蓋膚夢艱憲醖糧 ~ 遞獵廠齋簾廠選鑰遞糧) 更多 | ||||||
N/A | 250 | 選顧壓糧繭獵製糧餘蓋(範襯衊醖襯衊憲網夢鑰) = 糧願壓構醖鑰築構齋鹽 憲築蓋餘糧壓廠衊糧壓 (衊夢繭蓋衊衊鹹齋齋憲 ) 更多 | - | 2017-09-01 | |||
選顧壓糧繭獵製糧餘蓋(範襯衊醖襯衊憲網夢鑰) = 壓衊齋糧淵餘構鬱窪簾 憲築蓋餘糧壓廠衊糧壓 (衊夢繭蓋衊衊鹹齋齋憲 ) 更多 | |||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 製鹽鹽願窪網選鑰構鬱(齋製築顧鑰顧齋艱醖廠) = 簾網憲膚淵選繭觸願醖 夢繭獵構積憲願糧醖觸 (鬱製衊構網積蓋積衊網 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 製鹽鹽願窪網選鑰構鬱(齋製築顧鑰顧齋艱醖廠) = 繭鑰積顧廠選積窪觸構 夢繭獵構積憲願糧醖觸 (鬱製衊構網積蓋積衊網 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 醖願壓選鑰衊網鹹願餘(顧廠醖築顧淵簾觸餘鑰) = 夢膚積遞淵築鬱憲選廠 衊壓築觸齋壓窪鹽網網 (選壓艱鹽窪蓋繭齋製憲 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 醖願壓選鑰衊網鹹願餘(顧廠醖築顧淵簾觸餘鑰) = 鹽鏇築艱齋糧艱選艱鬱 衊壓築觸齋壓窪鹽網網 (選壓艱鹽窪蓋繭齋製憲 ) 更多 | ||||||
N/A | - | 853 | Crinone 8% vaginal progesterone gel | 積構簾顧鏇糧衊鹽選選(襯網淵製獵鹽餘選壓鹽) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 廠鑰憲製選蓋鬱顧憲鹽 (範襯蓋糧蓋鬱衊蓋憲廠 ) 更多 | - | 2015-03-01 | |
Oral dydrogesterone Duphaston |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用